Cognition Therapeutics to Give Webcast Presentation at Annual Piper Jaffray Healthcare Conference on December 3, 2019
20 nov. 2019 08h03 HE
|
Cognition Therapeutics, Inc.
PITTSBURGH, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
Cognition Therapeutics Expands Leadership Team with Appointment of James M. O’Brien as Chief Financial Officer
04 nov. 2019 08h02 HE
|
Cognition Therapeutics, Inc.
PITTSBURGH, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
Cognition Therapeutics to Present Findings from the Elayta™ Clinical Development Program at Society for Neuroscience Annual Meeting
10 oct. 2019 08h02 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
Cognition Therapeutics Extends IP Coverage of Alzheimer’s Therapeutic Elayta™ to Additional Major Pharmaceutical Markets with Patent Issuances in Japan and China
24 juil. 2019 09h27 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, July 24, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
Cognition Therapeutics Elects Lisa Ricciardi to its Board of Directors
26 mars 2019 09h51 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, March 26, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative...
Cognition Therapeutics Receives European Patent Covering its Alzheimer's Disease Candidate, Elayta™
21 févr. 2019 08h03 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative...
Cognition Therapeutics Announces Publication of Complete Results from Phase 1 Clinical Trial of Elayta™
19 févr. 2019 08h02 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative...
Cognition Therapeutics Expands Industry-Leading Expertise in Research and Clinical Use of Biomarkers of Alzheimer’s Disease
27 nov. 2018 08h03 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative...
Cognition Therapeutics to Sponsor Third International Symposium on Sigma-2 Receptors: Role in Health and Disease during the Society for Neuroscience Annual Meeting
24 oct. 2018 11h40 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic protection and restoration in Alzheimer’s disease and other...